Northern Trust Corporation Common Stock vs Novartis AG — how do they compare? Northern Trust Corporation Common Stock trades at $162.48 (market cap $30.63B), while Novartis AG trades at $149.5 (market cap $271.82B). The key difference: Novartis AG is far larger — about 8.9× Northern Trust Corporation Common Stock's market cap, and Novartis AG pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Northern Trust Corporation Common Stock for 0 Days and Novartis AG for 82 Days on average.
| NTRS | NVS | |
|---|---|---|
Market Cap | $30.63B | $271.82B |
Volume | 964,550 | 1,841,354 |
Sector | Financials | Health |
52-Week High | $191.47 | $168.62 |
52-Week Low | $122.72 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | -$5.35B | $313.15B |
Dividend Yield | 1.96% | 3.33% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVS trades at $146.88, up 2.11% today, with a bearish technical signal from moving averages and an overbought RSI. The company reported revenue of $56.67B in 2025, with a net income margin of 22.5%, and recently announced a $7.8B licensing deal with China's Abogen for RNA-based therapy. Earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026.
The outlook is cautious due to recent clinical trial setbacks and investor scrutiny of M&A strategy. Analyst consensus is a $146 price target with a hold-heavy rating. Risks include pipeline failures and competitive pressures, but strong cash flow and profitability provide support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →